Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.,Clinical & Experimental Ophthalmology

当前位置： X-MOL 学术 › Clin. Exp. Ophthalmol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Clinical & Experimental Ophthalmology ( IF 4 ) Pub Date : 2020-05-28 , DOI: 10.1111/ceo.13798
Shaan Wiryasaputra _{1,

2} , Vuong Nguyen ₁ , Jennifer J Arnold ₃ , Ross Ferrier ₄ , Peter Hinchcliffe ₅ , Daniel Barthelmes _{1,

6} , Mark C Gillies ₁

Affiliation

To assess early outcomes of intravitreal vascular endothelial growth factor (VEGF) inhibitor treatment in neovascular age‐related macular degeneration (nAMD) before patients have a chance to miss or discontinue treatment.

中文翻译：